ReviewInternational journal of urology : official journal of the Japanese Urological Association2024
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Review in International journal of urology : official journal of the Japanese Urological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Real-world perioperative systemic treatment patterns and postoperative mortality in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy in Japan: WAKKA-UTUC study.International journal of clinical oncology · 2026Article
- Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.European urology open science · 2026Article
- Rapid Systemic Progression After Ureteroscopic Holmium:YAG Laser Ablation for High-Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report.IJU case reports · 2026Article
- Article
- Article
- JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.ESMO real world data and digital oncology · 2025Article
- JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.Scientific reports · 2025Observational
- Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance.Cancer medicine · 2025Article
- Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.Cancer medicine · 2025Article
- Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.Scientific reports · 2025Article
- Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma.Scientific reports · 2025Article
- Letter to the editor for the article "Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma".World journal of urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article is an English translation of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma (2nd edition) published in June 2023. The Japanese Urological Association's (JUA) Guidelines Committee on Upper Tract Urothelial Carcinoma (UTUC) created a 2023 update guideline to support clinicians' current evidence-based management of UTUC and to incorporate its recommendations into clinical practice. The new guideline adhered as closely as possible to the Minds Manual for Guideline Development 2020 ver. 3.0. Findings related to epidemiological, pathological, diagnosis, treatment, and follow-up were reviewed. In addition, seven clinical questions (CQs) were set to determine the grade of recommendation and level of evidence. Preconceptions and biases were removed from the preparation process, the overall evidence was evaluated appropriately, and recommendations were made after fully considering the balance between benefits and harms. Although the evidence is still insufficient to be taken up as a CQ, the latest important information is described in seven columns, and clinical issues that should be resolved in the future related to the CQ are described as recommendations for tomorrow. We hope that these guidelines will help medical professionals, patients, and their families involved in the treatment of UTUC in their decision-making, and hope that a critical review of these guidelines will lead to further refinements in the next edition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.